Reported Earnings • May 27
Full year 2026 earnings released: ₹0.22 loss per share (vs ₹2.37 loss in FY 2025) Full year 2026 results: ₹0.22 loss per share (improved from ₹2.37 loss in FY 2025). Revenue: ₹1.05b (up 14% from FY 2025). Net loss: ₹19.2m (loss narrowed 90% from FY 2025). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Ankündigung • May 20
JHS Svendgaard Laboratories Limited to Report Q4, 2026 Results on May 26, 2026 JHS Svendgaard Laboratories Limited announced that they will report Q4, 2026 results on May 26, 2026 Reported Earnings • Feb 12
Third quarter 2026 earnings released: EPS: ₹0.09 (vs ₹0.21 loss in 3Q 2025) Third quarter 2026 results: EPS: ₹0.09 (up from ₹0.21 loss in 3Q 2025). Revenue: ₹238.5m (up 4.0% from 3Q 2025). Net income: ₹7.89m (up ₹26.3m from 3Q 2025). Profit margin: 3.3% (up from net loss in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Ankündigung • Feb 04
JHS Svendgaard Laboratories Limited to Report Q3, 2026 Results on Feb 10, 2026 JHS Svendgaard Laboratories Limited announced that they will report Q3, 2026 results on Feb 10, 2026 New Risk • Jan 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹132m free cash flow). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (₹929.7m market cap, or US$10.3m). New Risk • Nov 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹880.9m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹132m free cash flow). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (₹880.9m market cap, or US$9.88m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • Nov 16
Second quarter 2026 earnings released: ₹0.02 loss per share (vs ₹1.24 loss in 2Q 2025) Second quarter 2026 results: ₹0.02 loss per share (improved from ₹1.24 loss in 2Q 2025). Revenue: ₹234.2m (up 14% from 2Q 2025). Net loss: ₹1.98m (loss narrowed 98% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 18% per year. Ankündigung • Nov 08
JHS Svendgaard Laboratories Limited to Report Q2, 2026 Results on Nov 13, 2025 JHS Svendgaard Laboratories Limited announced that they will report Q2, 2026 results on Nov 13, 2025 New Risk • Oct 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹157m free cash flow). Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (₹1.03b market cap, or US$11.7m). Ankündigung • Aug 28
JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 20, 2025 JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 20, 2025, at 13:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2026 earnings released: EPS: ₹0.12 (vs ₹0.08 loss in 1Q 2025) First quarter 2026 results: EPS: ₹0.12 (up from ₹0.08 loss in 1Q 2025). Revenue: ₹244.5m (down 1.4% from 1Q 2025). Net income: ₹10.6m (up ₹16.8m from 1Q 2025). Profit margin: 4.3% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Ankündigung • Aug 09
JHS Svendgaard Laboratories Limited to Report Q1, 2026 Results on Aug 12, 2025 JHS Svendgaard Laboratories Limited announced that they will report Q1, 2026 results on Aug 12, 2025 New Risk • Jun 04
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹157m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹157m free cash flow). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹1.16b market cap, or US$13.5m). Buy Or Sell Opportunity • May 23
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 1.9% to ₹14.38. The fair value is estimated to be ₹11.87, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Ankündigung • May 13
JHS Svendgaard Laboratories Limited to Report Q4, 2025 Results on May 17, 2025 JHS Svendgaard Laboratories Limited announced that they will report Q4, 2025 results at 12:08 PM, Indian Standard Time on May 17, 2025 Buy Or Sell Opportunity • May 07
Now 21% overvalued Over the last 90 days, the stock has fallen 24% to ₹14.53. The fair value is estimated to be ₹11.99, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Apr 08
Now 21% overvalued Over the last 90 days, the stock has fallen 31% to ₹14.50. The fair value is estimated to be ₹11.95, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Mar 07
Now 24% overvalued Over the last 90 days, the stock has fallen 41% to ₹14.17. The fair value is estimated to be ₹11.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Feb 19
Now 28% overvalued Over the last 90 days, the stock has fallen 30% to ₹14.97. The fair value is estimated to be ₹11.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. New Risk • Feb 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 51% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-₹129m). Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₹1.15b market cap, or US$13.2m). Ankündigung • Feb 14
JHS Svendgaard Laboratories Limited Appoints Paramvir Singh as A Director JHS Svendgaard Laboratories Limited at its postal Ballot held on February 10, 2025, approved the appointment of Mr. Paramvir Singh (Din: 00098684) as A Director of the Company. RESOLVED THAT pursuant to the provisions of Sections 149, 152, 160 and all other applicable provisions, if any, of the Companies Act, 2013 (`the Act'), read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and other applicable rules, if any [including any statutory modification(s) or amendment(s) or re-enactment(s) thereof for the time being in force, Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and subject to the provisions of Articles of Association of the Company and based on the recommendation of the Nomination & Remuneration Committee and the approval of the Board of Directors of the Company, Mr. Paramvir Singh (DIN: 00098684), who was appointed as an Additional Director of the Company with effect from November 13, 2024 pursuant to the provisions of Section 161 and other applicable provisions of the Act to hold office up to the date of the General Meeting and in respect of whom the Company has received a notice in writing under Section 160 of the Act, proposing his candidature for the office of Director, be and is hereby appointed as a Director of the Company, liable to retire by rotation. Reported Earnings • Feb 13
Third quarter 2025 earnings released: ₹0.21 loss per share (vs ₹0.002 profit in 3Q 2024) Third quarter 2025 results: ₹0.21 loss per share (down from ₹0.002 profit in 3Q 2024). Revenue: ₹229.3m (up 38% from 3Q 2024). Net loss: ₹18.4m (down ₹18.5m from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Ankündigung • Feb 07
JHS Svendgaard Laboratories Limited to Report Q3, 2025 Results on Feb 11, 2025 JHS Svendgaard Laboratories Limited announced that they will report Q3, 2025 results on Feb 11, 2025 Reported Earnings • Nov 15
Second quarter 2025 earnings released: ₹1.24 loss per share (vs ₹0.09 loss in 2Q 2024) Second quarter 2025 results: ₹1.24 loss per share (further deteriorated from ₹0.09 loss in 2Q 2024). Revenue: ₹205.4m (up 7.4% from 2Q 2024). Net loss: ₹103.2m (loss widened ₹95.9m from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Ankündigung • Nov 09
JHS Svendgaard Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024 JHS Svendgaard Laboratories Limited announced that they will report Q2, 2025 results on Nov 13, 2024 New Risk • Sep 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (9.2% increase in shares outstanding). Market cap is less than US$100m (₹2.62b market cap, or US$31.3m). Ankündigung • Aug 14
JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 10, 2024 JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 10, 2024, at 13:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2025 earnings released: ₹0.08 loss per share (vs ₹0.40 loss in 1Q 2024) First quarter 2025 results: ₹0.08 loss per share (improved from ₹0.40 loss in 1Q 2024). Revenue: ₹248.0m (up 22% from 1Q 2024). Net loss: ₹6.29m (loss narrowed 77% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Ankündigung • Aug 07
JHS Svendgaard Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024 JHS Svendgaard Laboratories Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Ankündigung • Jun 06
JHS Svendgaard Laboratories Limited announced that it expects to receive INR 300 million in funding from COEUS Global Opportunities Fund, M.B. Finmart Private Limited, Milky Investment And Trading Company, Puran Associates Pvt. Ltd., Vic Enterprises Private Limited and another investor JHS Svendgaard Laboratories Limited announced a private placement to issue common shares for the gross proceeds of INR 200,000,000 million and convertible warrants for the gross proceeds of INR 100,000,000; aggregate gross proceeds of INR 300,000,000 on June 4, 2024. The transaction will include participation from Puran Associates Private Limited for INR 50,000,000, Milky Investment and Trading Company for INR 50,000,000, M.B. Finmart Private Limited for INR 50,000,000 and VIC Enterprises Private Limited for INR 50,000,000 and warrants Nikhil Nanda for INR 50,000,000 and Coeus Global Opportunities Fund for INR 50,000,000. The transaction has been approved by shareholders and is subject to general shareholders which is to be held on July 04,2024 to seek necessary approval of the Shareholders for the proposed Preferential Issue. Ankündigung • May 12
JHS Svendgaard Laboratories Limited to Report Q4, 2024 Results on May 18, 2024 JHS Svendgaard Laboratories Limited announced that they will report Q4, 2024 results at 4:00 PM, Indian Standard Time on May 18, 2024 Reported Earnings • Feb 16
Third quarter 2024 earnings released: EPS: ₹0.002 (vs ₹0.24 loss in 3Q 2023) Third quarter 2024 results: EPS: ₹0.002 (up from ₹0.24 loss in 3Q 2023). Revenue: ₹166.4m (down 35% from 3Q 2023). Net income: ₹126.0k (up ₹15.4m from 3Q 2023). Profit margin: 0.1% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Ankündigung • Feb 05
JHS Svendgaard Laboratories Limited to Report Nine Months, 2024 Results on Feb 14, 2024 JHS Svendgaard Laboratories Limited announced that they will report nine months, 2024 results on Feb 14, 2024 New Risk • Jan 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹220m free cash flow). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 58% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₹2.33b market cap, or US$28.0m). New Risk • Dec 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹220m free cash flow). Earnings have declined by 58% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₹2.22b market cap, or US$26.6m). Reported Earnings • Nov 09
Second quarter 2024 earnings released: ₹0.09 loss per share (vs ₹0.03 loss in 2Q 2023) Second quarter 2024 results: ₹0.09 loss per share (further deteriorated from ₹0.03 loss in 2Q 2023). Revenue: ₹191.3m (down 21% from 2Q 2023). Net loss: ₹7.30m (loss widened 237% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Ankündigung • Nov 01
JHS Svendgaard Laboratories Limited to Report First Half, 2024 Results on Nov 07, 2023 JHS Svendgaard Laboratories Limited announced that they will report first half, 2024 results on Nov 07, 2023 Ankündigung • Oct 17
JHS Svendgaard Laboratories Limited Announces the Resignation of Mr. Deepesh Sharma as Joint Chief Financial Officer JHS Svendgaard Laboratories Limited announced the resignation of Mr. Deepesh Sharma as Joint Chief Financial Officer, with immediate effect due to some personal reasons. Ankündigung • Sep 17
JHS Svendgaard Laboratories Limited Announces Cessation of Rohina Sanjay Sangtani as Independent Director JHS Svendgaard Laboratories Limited announced that in continuation to its earlier intimation dated 11 September, 2018 wherein it was informed the Exchange that Mrs. Rohina Sanjay Sangtani was appointed as an Independent Director for a term of 5 consecutive years with effect from 11 September 2018 to hold the office till 10 September, 2023. In this connection, the company to clarify that the tenure of the aforementioned director i.e. Mrs. Rohina Sanjay Sangtani has been expired. New Risk • Sep 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 61% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₹1.86b market cap, or US$22.4m). Ankündigung • Sep 06
JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 28, 2023 JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 28, 2023, at 14:00 Indian Standard Time. Agenda: To consider, and if thought fit, to pass the following Resolution as an Ordinary Resolution; To consider and, if thought fit, to pass the following Resolution as an Ordinary Resolution. Ankündigung • Aug 17
JHS Svendgaard Laboratories Limited (NSEI:JHS) agreed to acquire Vedic Cosmeceuticals Pvt. Ltd. JHS Svendgaard Laboratories Limited (NSEI:JHS) agreed to acquire Vedic Cosmeceuticals Pvt. Ltd. on August 14, 2023. The transaction has been approved by board of JHS Svendgaard Laboratories. Reported Earnings • Aug 16
First quarter 2024 earnings released: ₹0.40 loss per share (vs ₹0.59 loss in 1Q 2023) First quarter 2024 results: ₹0.40 loss per share (improved from ₹0.59 loss in 1Q 2023). Revenue: ₹203.7m (down 4.4% from 1Q 2023). Net loss: ₹27.4m (loss narrowed 29% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Ankündigung • Aug 08
JHS Svendgaard Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023 JHS Svendgaard Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023 New Risk • Jun 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.40b market cap, or US$17.1m). Reported Earnings • Jun 04
Full year 2023 earnings released: ₹2.34 loss per share (vs ₹0.63 loss in FY 2022) Full year 2023 results: ₹2.34 loss per share (further deteriorated from ₹0.63 loss in FY 2022). Revenue: ₹1.11b (up 28% from FY 2022). Net loss: ₹154.6m (loss widened 282% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Ankündigung • May 31
JHS Svendgaard Laboratories Limited Appoints Deepesh Sharma as Joint Chief Financial Officer JHS Svendgaard Laboratories Limited at its Board meeting held on May 30, 2023 appointed Mr. Deepesh Sharma as Joint Chief Financial Officer of the Company w.e.f. May 30th 2023. Mr. Deepesh Sharma, Chartered Financial Analyst from The Institute of] Chartered Financial Analyst of India University, Tripura and possesses nearing 13 years experience as Investment Banker and Financial Analyst. Ankündigung • May 25
JHS Svendgaard Laboratories Limited to Report Q4, 2023 Results on May 30, 2023 JHS Svendgaard Laboratories Limited announced that they will report Q4, 2023 results on May 30, 2023 Reported Earnings • Feb 15
Third quarter 2023 earnings released: ₹0.24 loss per share (vs ₹0.04 profit in 3Q 2022) Third quarter 2023 results: ₹0.24 loss per share (down from ₹0.04 profit in 3Q 2022). Revenue: ₹271.2m (up 30% from 3Q 2022). Net loss: ₹15.3m (down ₹17.9m from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Ankündigung • Feb 15
JHS Svendgaard Laboratories Limited Announces the Resignation of Neeraj Kumar as Joint Chief Financial Officer, Effective March 15, 2023 JHS Svendgaard Laboratories Limited at the board meeting held on February 14, 2023, recorded the resignation of Mr. Neeraj Kumar from the post of Joint Chief Financial Officer due to personal reasons. The Company shall be relieving him from his responsibilities with effect from March 15, 2023 as per the Company's Policy and requisite update in this connection will be submitted to the stock exchanges in due course. Ankündigung • Feb 08
JHS Svendgaard Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023 JHS Svendgaard Laboratories Limited announced that they will report Q3, 2023 results on Feb 14, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: ₹0.03 loss per share (vs ₹0.05 profit in 2Q 2022) Second quarter 2023 results: ₹0.03 loss per share (down from ₹0.05 profit in 2Q 2022). Revenue: ₹274.9m (up 12% from 2Q 2022). Net loss: ₹2.16m (down 181% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Reported Earnings • Nov 12
Second quarter 2023 earnings released: ₹0.03 loss per share (vs ₹0.05 profit in 2Q 2022) Second quarter 2023 results: ₹0.03 loss per share (down from ₹0.05 profit in 2Q 2022). Revenue: ₹274.9m (up 12% from 2Q 2022). Net loss: ₹2.16m (down 181% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Reported Earnings • Aug 11
First quarter 2023 earnings released First quarter 2023 results: ₹0.59 loss per share. Revenue: ₹227.9m (up 5.6% from 1Q 2022). Net loss: ₹38.5m (loss widened ₹36.2m from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Reported Earnings • Jun 02
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: ₹0.63 loss per share (down from ₹0.20 profit in FY 2021). Revenue: ₹862.5m (down 15% from FY 2021). Net loss: ₹40.5m (down 438% from profit in FY 2021). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) missed analyst estimates. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 16% share price gain to ₹27.35, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 40x in the Personal Products industry in India. Total returns to shareholders of 22% over the past three years. Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improved over the past week After last week's 16% share price gain to ₹29.40, the stock trades at a trailing P/E ratio of 64.7x. Average trailing P/E is 46x in the Personal Products industry in India. Total returns to shareholders of 15% over the past three years. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improved over the past week After last week's 16% share price gain to ₹23.40, the stock trades at a trailing P/E ratio of 50.1x. Average trailing P/E is 44x in the Personal Products industry in India. Total loss to shareholders of 12% over the past three years. Reported Earnings • Feb 09
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: ₹0.04 (up from ₹0.02 in 3Q 2021). Revenue: ₹236.5m (down 12% from 3Q 2021). Net income: ₹2.65m (up 146% from 3Q 2021). Profit margin: 1.1% (up from 0.4% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 4.7%. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹26.20, the stock trades at a trailing P/E ratio of 68.2x. Average trailing P/E is 49x in the Personal Products industry in India. Negligible returns to shareholders over past three years. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 16% share price gain to ₹25.95, the stock trades at a trailing P/E ratio of 60x. Average trailing P/E is 40x in the Personal Products industry in India. Total loss to shareholders of 24% over the past three years. Reported Earnings • Nov 07
Second quarter 2022 earnings released: EPS ₹0.05 (vs ₹0.16 in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹263.3m (down 17% from 2Q 2021). Net income: ₹2.66m (down 73% from 2Q 2021). Profit margin: 1.0% (down from 3.1% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment improved over the past week After last week's 16% share price gain to ₹27.80, the stock trades at a trailing P/E ratio of 44.2x. Average trailing P/E is 48x in the Personal Products industry in India. Total returns to shareholders of 1.8% over the past three years. Reported Earnings • Jun 26
Full year 2021 earnings released: EPS ₹0.20 (vs ₹0.33 loss in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: ₹1.01b (down 29% from FY 2020). Net income: ₹12.0m (up ₹31.8m from FY 2020). Profit margin: 1.2% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 11
Third quarter 2021 earnings released: EPS ₹0.02 (vs ₹0.11 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹269.4m (down 27% from 3Q 2020). Net income: ₹1.08m (down 84% from 3Q 2020). Profit margin: 0.4% (down from 1.8% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Jan 29
New 90-day high: ₹26.90 The company is up 49% from its price of ₹18.10 on 30 October 2020. The Indian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 11% over the same period. Is New 90 Day High Low • Dec 16
New 90-day high: ₹26.60 The company is up 12% from its price of ₹23.70 on 17 September 2020. The Indian market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 6.0% over the same period. 
